arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2008-14-2-125-130arthyper-1200Research ArticleОБЗОРREVIEWНужно ли пациенту с артериальной гипертонией снижать ЧСС?Is it necessary to slow the heart rate in
a hypertensive patient?МаколкинВ.MakolkinB.noemail@neicon.ruМосковская медицинская академия им. И.М.СеченоваРоссияMoscow Sechenov Medical AcademyRussian Federation200828042008142125130Copyright © Маколкин
В., 20082008Маколкин
В.Makolkin
B.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/1200ReferencesОганов Р.Г. Развитие профилактической кардиологии в России. Кардиоваскулярная терапия и профилактика, 2004; 3(3),ч.1,с.10-14.Оганов Р.Г. Развитие профилактической кардиологии в России. Кардиоваскулярная терапия и профилактика, 2004; 3(3),ч.1,с.10-14.Levine H.J. Heart rate and life expectancy. J Amer Coll Card 1997;30:1104.Levine H.J. Heart rate and life expectancy. J Amer Coll Card 1997;30:1104.Spector W.S. Handbook of Biologocal Data, WB Saunders, Philadelphia,1956, p41.Spector W.S. Handbook of Biologocal Data, WB Saunders, Philadelphia,1956, p41.White P.D., Jenkins J.L., Benedict F.G. The electrocardiogram of the elephant. Am Heart J 1938 16:744.White P.D., Jenkins J.L., Benedict F.G. The electrocardiogram of the elephant. Am Heart J 1938 16:744.Boraso A. Why is reduced heart rate beneficial. Dialogues in Cardiovascular Medicine 2001; 6:19-24.Boraso A. Why is reduced heart rate beneficial. Dialogues in Cardiovascular Medicine 2001; 6:19-24.Schmidt-Nielsen K. Animal Phisiology: Adaptation and Environment. New York: Cambridge University Press, 1975, h 133.Schmidt-Nielsen K. Animal Phisiology: Adaptation and Environment. New York: Cambridge University Press, 1975, h 133.Beere P., Glagov S., Zarins C. Retarding effect of lowering heart rate on coronary atherosclerosis. Sciente 1984; 226:180-2.Beere P., Glagov S., Zarins C. Retarding effect of lowering heart rate on coronary atherosclerosis. Sciente 1984; 226:180-2.Perski A., Hamsted A., Lindvall K., Theorell T. Heart rate correlates with severity of coronary atherosclerosis in young postinfarction parients. Am Heart J 1988;116:1369-73.Perski A., Hamsted A., Lindvall K., Theorell T. Heart rate correlates with severity of coronary atherosclerosis in young postinfarction parients. Am Heart J 1988;116:1369-73.Castelli W.P., Levy D., Wilson P.W.F., Kannel W. Sudden death: The view from Framingham. In Kostis JB, Sanders M (eds). The Prevention of Sudden Death. E Wiley-Liss, New York, 1990, pp 1-8.Castelli W.P., Levy D., Wilson P.W.F., Kannel W. Sudden death: The view from Framingham. In Kostis JB, Sanders M (eds). The Prevention of Sudden Death. E Wiley-Liss, New York, 1990, pp 1-8.Pepine C.J., Handberg E., Cooper-De-Hoff R. et al. A Calcium Antagonist vs Non-Calcium Antagonist HypertensionTreatment Strategy for Patients With Coronary Artery Disease.The International Verapamil-Trandolapril Study (INVEST):A Randomized Controlled Trial. JAMA, December 3, 2003-Vol290, № 21:2805-2816.Pepine C.J., Handberg E., Cooper-De-Hoff R. et al. A Calcium Antagonist vs Non-Calcium Antagonist HypertensionTreatment Strategy for Patients With Coronary Artery Disease.The International Verapamil-Trandolapril Study (INVEST):A Randomized Controlled Trial. JAMA, December 3, 2003-Vol290, № 21:2805-2816.Novo S., Alaimo G., Abrignani M.G., Longo B., Muratore G., Strano A. Noninvasive blood pressure monitoring evaluation of verapamil slow-release 240-mg antihypertensive effectiveness. Journal of Cardiovascular Pharmacology 1989; 13 (Suppl. 4): S38-S41.Novo S., Alaimo G., Abrignani M.G., Longo B., Muratore G., Strano A. Noninvasive blood pressure monitoring evaluation of verapamil slow-release 240-mg antihypertensive effectiveness. Journal of Cardiovascular Pharmacology 1989; 13 (Suppl. 4): S38-S41.Safar M., Benetos A., Juvin Ph. et al. Multicentre trial of the antihypertensive efficacy and safety of Verapamil CP. Act. med. Int. - l'Hypertension 1990; 2: 3-7."Safar M., Benetos A., Juvin Ph. et al. Multicentre trial of the antihypertensive efficacy and safety of Verapamil CP. Act. med. Int. - l'Hypertension 1990; 2: 3-7."Holzgreve H., Distler, Michaelis J., Philipp Th., Wellek S. Verapamil versus hydrochlordthiazide in the treatment of hypertension: results of long term double blind comparrati ve trial. Br. Med. J. 1989; 299: 881-886.Holzgreve H., Distler, Michaelis J., Philipp Th., Wellek S. Verapamil versus hydrochlordthiazide in the treatment of hypertension: results of long term double blind comparrati ve trial. Br. Med. J. 1989; 299: 881-886.Stalmach W.J., Rush D.R., Brucker P.C., Holverson H., Huffmann B.L., Kane W.J., Ryan M.F. Managing hypertension in family practice: a nationwide collaborative study of the use of four antihypertensives in the treatment of mild-to-moderate hypertension. J. Amer. Fam. Pract. 1989;2:172-190.Stalmach W.J., Rush D.R., Brucker P.C., Holverson H., Huffmann B.L., Kane W.J., Ryan M.F. Managing hypertension in family practice: a nationwide collaborative study of the use of four antihypertensives in the treatment of mild-to-moderate hypertension. J. Amer. Fam. Pract. 1989;2:172-190.Libretti A. Catalono Mon behalf of the SLIP study gropup. Lipid profile during antihypertensive treatment - the SLIP study. Drugs 1993; 46 (Suppl. 2):16-23.Libretti A. Catalono Mon behalf of the SLIP study gropup. Lipid profile during antihypertensive treatment - the SLIP study. Drugs 1993; 46 (Suppl. 2):16-23.Agabiti Rosei E., Dal Plau C., Leonetti G. et al. The verapamil in hypertension and atherosclerosis study (YHAS): results of long-term randomised treatment with either verapamilor chlorthalidone on carotid intima-media thickness. J. Hypertens.1997;15:1337-1344.Agabiti Rosei E., Dal Plau C., Leonetti G. et al. The verapamil in hypertension and atherosclerosis study (YHAS): results of long-term randomised treatment with either verapamilor chlorthalidone on carotid intima-media thickness. J. Hypertens.1997;15:1337-1344.Zanchetti A., Magnani B., Dal Plau С. et al. Clinical results of the verapamil in hypertension and atherosclerosis study (VHAS). J. Hypertens. 1998; 16:1667-1676.Zanchetti A., Magnani B., Dal Plau С. et al. Clinical results of the verapamil in hypertension and atherosclerosis study (VHAS). J. Hypertens. 1998; 16:1667-1676.Lefrandt J.D., van Roon A.M., van Gessel et al. Improved Short-Term Blood Pressure Control by treatment with calcium antagonists in patients with mild or moderate hypertension. J Hypertension 1999, 17 (Suppl.3).Lefrandt J.D., van Roon A.M., van Gessel et al. Improved Short-Term Blood Pressure Control by treatment with calcium antagonists in patients with mild or moderate hypertension. J Hypertension 1999, 17 (Suppl.3).Diaz A., Bourassa M.G., Guertin M.C., Tardif J.C. Long-term value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; March 21.Diaz A., Bourassa M.G., Guertin M.C., Tardif J.C. Long-term value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; March 21.Grossman E., Messerli F.H. Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure. Am J Cardiol 1997; 80:1453-1458.Grossman E., Messerli F.H. Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure. Am J Cardiol 1997; 80:1453-1458.Silber S., Vogler A., Theisen K. Equal anti-ischemic properties of isosorbide dinitrate plus propranolol - a randomised, double-blind and crossover study. Z. Kardiol., Suppl.3 (1986), 100-105.Silber S., Vogler A., Theisen K. Equal anti-ischemic properties of isosorbide dinitrate plus propranolol - a randomised, double-blind and crossover study. Z. Kardiol., Suppl.3 (1986), 100-105.Pallone N.M. Effect of Calcium Antagonists in the Treatment of Silent Ischemic Heart Disease. Curr. Ther. Res., 45 (1989), 339-346.Pallone N.M. Effect of Calcium Antagonists in the Treatment of Silent Ischemic Heart Disease. Curr. Ther. Res., 45 (1989), 339-346.Danish S.G. on Vin M.I. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II - DAVIT II). Am J Cardiol 1990 Oct;66:779-85.Danish S.G. on Vin M.I. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II - DAVIT II). Am J Cardiol 1990 Oct;66:779-85.Rengo F., Carbon P., Pathor M. et al. A conrolled trial in patients after myocardial infarction: results of the Calcium antagonist Reinfarction Italian Studv. Am. J. Cardiol. 1996; 77: 365-369.Rengo F., Carbon P., Pathor M. et al. A conrolled trial in patients after myocardial infarction: results of the Calcium antagonist Reinfarction Italian Studv. Am. J. Cardiol. 1996; 77: 365-369.Agabiti Rosei E., Dal Plau C., Leonetti G. et al. The verapamil in hypertension and atherosclerosis study (YHAS): results of long-term randomised treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J. Hypertens. 1997; 15:1337-1344.Agabiti Rosei E., Dal Plau C., Leonetti G. et al. The verapamil in hypertension and atherosclerosis study (YHAS): results of long-term randomised treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J. Hypertens. 1997; 15:1337-1344.Forslund L., Bjorkander I., Ericksson S. et al. Effect of metoprolol or verapamil treatment on results from exercise testingand long-term ECG recording in stable angina pectoris, Short-term results from the APSIS study. Eur Heart J 1995; 16 AbstractSuppl:422.Forslund L., Bjorkander I., Ericksson S. et al. Effect of metoprolol or verapamil treatment on results from exercise testingand long-term ECG recording in stable angina pectoris, Short-term results from the APSIS study. Eur Heart J 1995; 16 AbstractSuppl:422.Heidland U.E., Strauer B.E. Left ventricular vuscle mass and elevated heart rate are associated with coronary plaque di C Puption.Circulation, 2001;104:1477-1482.Heidland U.E., Strauer B.E. Left ventricular vuscle mass and elevated heart rate are associated with coronary plaque di C Puption.Circulation, 2001;104:1477-1482.
The authors declare that there are no conflicts of interest present.